AR-13503

AR-13503 (AR-13324 M1 metabolite) is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research[1][2][3].

Product Specifications

CAS Number

[2309668-15-1]

Product Name Alternative

AR-13324 M1 metabolite

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PKC; ROCK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ar-13503.html

Purity

98.21

Solubility

DMSO : 40 mg/mL (ultrasonic; adjust pH to 3 with HCl)

Smiles

OCC1=CC=C([C@@H](CN)C(NC2=CC(C=CN=C3)=C3C=C2)=O)C=C1

Molecular Formula

C19H19N3O2

Molecular Weight

321.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 205-205.|[2]Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 200-200.|[3]Halasz E, et al. AR-13503, a ROCK inhibitor, reduces rod axon retraction during retinal detachment[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 4221-4221.